EIF4A2

Across TCGA pan-cancer cohorts, EIF4A2 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of EIF4A2’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where EIF4A2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types EIF4A2 is over-expressed in tumor, although a few such as CCRCC and COAD show the opposite, repressed pattern.

CCRCC, COAD, and PDAC are the cancer types where EIF4A2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in EIF4A2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	IV	−0.510	<.001	11	view →
COAD	Male	II,III,IV	−0.465	<.001	9	view →
PDAC	Female	All	−0.528	<.001	8	view →
LUAD	Female	All	−0.138	<.001	8	view →
HNSC	All	II,III,IV	−0.192	.002	5	view →
LSCC	Male	III,IV	+0.164	.029	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

EIF4A2–CCRCC

Open the CCRCC breakdown →